Overview

Clinical Evaluation of [68Ga]Ga-NOTA-RF PET Imaging Targeting RFVT3 in Patients With Pituitary Tumors

Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-10-13
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the clinical application value of \[68Ga\]Ga-NOTA-RF, a novel PET molecular probe targeting riboflavin transporter 3 (RFVT3), in patients with pituitary adenomas. It will observe the probe's imaging characteristics, distribution signs, and the relationships between these factors, tumor differentiation degree, and radiotracer uptake. Additionally, the study will explore the diagnostic advantages of \[68Ga\]Ga-NOTA-RF in patients with pituitary adenomas and its potential value in precise typing.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Peking Union Medical College Hospital